New rapid test could speed up UTI diagnosis and antibiotic choice

NCT ID NCT06824129

Ongoing Diagnosis Sponsor: QIAGEN Gaithersburg, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study evaluates a new test called the QIAstat-Dx cUTI Plus AMR Panel, which aims to quickly detect bacteria and antibiotic resistance in urine samples from people with suspected complicated urinary tract infections (cUTI). Researchers will enroll 1500 participants of all ages to see how well the test works compared to standard lab methods. If accurate, this test could help doctors choose the right antibiotic faster, but it is still being tested and is not yet proven to improve patient care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QIAstat-Dx cUTI Plus AMR Panel (diagnostic test)
What this could lead to: If successful, this test could help doctors quickly identify the right antibiotic for complicated UTIs, potentially improving treatment and reducing antibiotic misuse.
What could go wrong: This is a performance evaluation, not a treatment trial. The test may not be more accurate than current methods, and results may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPLICATED URINARY TRACT INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMPLICATED URINARY TRACT INFECTION

Contacts and locations

Locations

QIAGEN

Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.